I have not kept up with the HCQ trials. I know tha
Post# of 148117
I believe that there is likely a place for HCQ, as there may be for a number of the antiparasitic drugs with demonstrated antiviral effects.
The question is for which patients, at what time, in which dose and by what means of administration. All difficult things to determine.
This is in large part why I am a bit concerned with the reactions we allow ourselves to have when the path to EUA and approval is not as straight or as short as we would like.
That is the nature of medicine and science, as well as life.
I know enough of the science of this drug to have made a huge (for me) financial commitment. I believe the investigator and regulatory processes are transparent enough that we will get there, even if the wheels are not greased as they are for other. Also part of life.